Product Information
COTEMPLA XR-ODT 17.3 MG TABLET is a brand product labeled by Neos Therapeutics Brands, LLC, priced at $17.9355 per EA under NDC 70165020030. Its NADAC has been published 449 times since Jan 17, 2018.
FDA first approved this application on Jun 19, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Methylphenidate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
17.3 mg/1
Manufacturer
Neos Therapeutics Brands, LLCNDC
70165020030
Classification
Brand
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
METHYLPHENIDATEApproval Type
New Drug (NDA)
FDA Application
NDA205489FDA Approved
6/19/2017
TE Code
AB
On Market Since
6/20/2017
Pharmacological Classes
Price Statistics
The NADAC for COTEMPLA XR-ODT 17.3 MG TABLET has been published 449 times since Jan 17, 2018, and over the history we have for it it has risen 75.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.9355 per EA |
|---|---|
| All-time high | $18.0380 (Aug 12, 2026) |
| All-time low | $10.2304 (Jan 17, 2018) |
| 52-week high | $18.0380 |
| 52-week low | $17.0932 |
| Median price | $14.3192 |
| Average price | $14.4044 |
| Largest weekly change | +13.2% (Jan 1, 2020) |
| Weeks tracked | 449 |
| Tracking since | Jan 17, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methylphenidate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of COTEMPLA XR-ODT 17.3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for COTEMPLA XR-ODT 17.3 MG TABLET, manufactured by Neos Therapeutics Brands, LLC, is $17.9355 per EA (NDC 70165020030), effective Aug 19, 2026.
How has the price of COTEMPLA XR-ODT 17.3 MG TABLET changed over time?
Over the history we have for it, the NADAC for COTEMPLA XR-ODT 17.3 MG TABLET has risen 75.3%. It has been tracked across 449 weekly CMS publications since Jan 17, 2018.
What are the highest and lowest recorded NADAC prices for COTEMPLA XR-ODT 17.3 MG TABLET?
Since Jan 17, 2018, the NADAC for COTEMPLA XR-ODT 17.3 MG TABLET has ranged from a low of $10.2304 (Jan 17, 2018) to a high of $18.0380 (Aug 12, 2026), with a median of $14.3192 per EA.
Are there cheaper alternatives to COTEMPLA XR-ODT 17.3 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of COTEMPLA XR-ODT 17.3 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures COTEMPLA XR-ODT 17.3 MG TABLET?
COTEMPLA XR-ODT 17.3 MG TABLET (NDC 70165020030) is labeled by Neos Therapeutics Brands, LLC, and CMS classifies it as a brand product.